– USA, MA – Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced the appointments of Dr. Elisabeth Svanberg and Jim Hindman to its Board of Directors following AGM held on June 30, 2021.
“I am very pleased to welcome Dr. Elisabeth Svanberg and James Hindman as new directors to our Board of Directors and look forward to leveraging their extensive clinical and financial expertise,” said Board Chairman, Pierre Legault. “I believe their guidance will serve the company well as it continues to advance its lead product candidate, AZP-3601, through clinical development for the potential treatment of hypoparathyroidism, while further expanding its product portfolio for rare endocrine and related diseases.”
About James Hindman
Mr. Hindman served for more than three decades in financial roles of increasing responsibility at Allergan, where he was instrumental in supporting that company’s development, which ultimately led to Actavis’ acquisition of Allergan in 2015. During his 30-plus year tenure at Allergan, Mr. Hindman held various senior leadership positions, including executive vice president of finance and business development and chief financial officer, as well as senior vice president, finance, and controller. Additionally, he served as president of the Allergan Foundation from 2009-2015. Mr. Hindman earned his MBA from Pepperdine University and his B.S. in accounting from Loyola Marymount University. He currently serves as director of Accuray Incorporated and Aatru Medical, Inc. and is a member of the Loyola Marymount University Board of Regents.
Mr. Hindman added, “I am impressed with the progress the Amolyt team has made in recent months, and believe the company is well-positioned to pursue its goal of developing potential new treatments for rare endocrine and related disorders for which new therapies are urgently needed. I look forward to working with the Board, and I am eager to play a part in helping Amolyt achieve its goals, particularly as it continues to build out its US-based presence.”
About Dr. Elisabeth Svanberg
Dr. Svanberg has extensive experience in the development of novel treatments for a range of endocrine, metabolic, and other high-need diseases. She currently serves as chief development officer at Ixaltis SA, a specialty pharmaceutical company developing proprietary therapeutics to treat genitourinary disorders with unmet medical needs. Before Ixaltis, she served as vice president, head of established products at Janssen Pharmaceuticals (a Johnson & Johnson Company), and as development leader for first-in-class novel diabetes medicine and subsequently as head of medical affairs for the intercontinental region at Bristol Myers Squibb. Earlier in her career, Dr. Svanberg worked for Serono International in roles of increasing responsibility, initially in the field of metabolism. Dr. Svanberg serves as a non-executive director on the boards of Egetis AB (formerly PledPharma AB), Swedish Orphan Biovitrum AB, Galapagos, and Pharnext SA.
Dr. Svanberg commented, “I am thrilled to join Amolyt’s Board of Directors as the company generates clinical data in its Phase I trial for its lead product candidate, AZP-3601. I believe AZP-3601 represents a potential advancement in the treatment of hypoparathyroidism, and I am excited to support the company’s goal of building a portfolio of products targeted toward rare endocrine and related diseases, an area with high unmet medical needs. I look forward to working alongside my colleagues on the Amolyt board to help support the development of this portfolio.”
Dr. Svanberg received her M.D. and Ph.D. from the University of Gothenburg, Sweden and is a board-certified general surgeon and associate professor of surgery.
About Amolyt Pharma
Amolyt Pharma is building on its team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Its portfolio includes AZP-3601 as a potential treatment of hypoparathyroidism, AZP-38XX, a small peptide series under evaluation to select a development candidate for the treatment of acromegaly, and AZP-3404, which is undergoing indication selection work. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
For more information: https://amolytpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.